|Articles|December 15, 2002
- BioPharm International-12-15-2002
- Volume 15
- Issue 1
Guest Editorial: EPO Saga to Augur Regulatory Change?
Author(s)Gordon Kelley
by Gordon Kelley, BioPharm International magazine
Advertisement
Articles in this issue
almost 23 years ago
BioPharm International Five-Year Article Indexalmost 23 years ago
Evaluation of Extractables from Product-Contact Surfacesalmost 23 years ago
Monitoring and Controlling Biocatalytic ProcessesNewsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Advertisement
Advertisement
Advertisement
Trending on BioPharm International
1
Regulatory Uncertainty Surfaces as FDA Blames COVID Vaccines for 10 Child Deaths
2
New Draft Guidance Highlights FDA Push Toward Human-Relevant Safety Models
3
Implementing Automation and Flexible Design for Allogeneic Manufacturing
4
Rentschler–Coriolis Partnership Reflects Demand for Connected Biopharma Workflows
5
